2023-510488-36-01
EU Clinical Trials Information System
- Trial ID
- T-ctis-2023-510488-36-01
- Registry
- EU Clinical Trials Information System
- CTIS number
- 2023-510488-36-01
- Sponsor, as registered
- Universitair Medisch Centrum Groningen
- Phase
- Therapeutic exploratory (Phase II)
- Indication
- Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).
- Status
- Authorised
- Start date
- 2025-06-01
- Primary completion
- CTIS does not publish one.
- Member states concerned
- Czechia, Denmark, Netherlands, Portugal
- Sites
- 4
Member states whose regulator has a decision on this trial.
euclinicaltrials.euctis registryverified 2026-09-28
Notes on the record
countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date. Per-state authorisation is in data/decisions.csv. PsyPal: psilocybin therapy for psychological distress in palliative care; sponsor Universitair Medisch Centrum Groningen; Phase II; DK, CZ, PT, NL. Added 2026-09-28 because the record carried a publication update inside the 21 to 28 September window (lastUpdated 22/09/2026, lastPublicationUpdate 23/09/2026); what changed is not published by the API. No asset row: investigator-led psilocybin with no asset_id assigned this session. Read 2026-09-28. ctPublicStatusCode on the retrieve endpoint was 3, stored as Authorised, the same mapping the file uses for codes 3 to 5 on the existing brenipatide rows.
Cited in
No published issue cites this registry number.